1. Home
  2. QNST vs ACRS Comparison

QNST vs ACRS Comparison

Compare QNST & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo QuinStreet Inc.

QNST

QuinStreet Inc.

HOLD

Current Price

$18.30

Market Cap

1.1B

ML Signal

HOLD

Logo Aclaris Therapeutics Inc.

ACRS

Aclaris Therapeutics Inc.

HOLD

Current Price

$5.48

Market Cap

868.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
QNST
ACRS
Founded
1999
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Business Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
868.5M
IPO Year
2009
2015

Fundamental Metrics

Financial Performance
Metric
QNST
ACRS
Price
$18.30
$5.48
Analyst Decision
Buy
Strong Buy
Analyst Count
4
5
Target Price
$24.75
$10.20
AVG Volume (30 Days)
812.2K
1.9M
Earning Date
05-07-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
1650.00
69.01
EPS
1.40
N/A
Revenue
$282,140,000.00
$1,683,000.00
Revenue This Year
$18.59
N/A
Revenue Next Year
$14.80
$4.24
P/E Ratio
$13.13
N/A
Revenue Growth
N/A
N/A
52 Week Low
$10.29
$1.74
52 Week High
$22.29
$6.60

Technical Indicators

Market Signals
Indicator
QNST
ACRS
Relative Strength Index (RSI) 48.38 45.15
Support Level $11.08 $4.13
Resistance Level $21.23 $5.87
Average True Range (ATR) 0.77 0.34
MACD -0.28 -0.11
Stochastic Oscillator 31.02 32.87

Price Performance

Historical Comparison
QNST
ACRS

About QNST QuinStreet Inc.

QuinStreet Inc focuses on marketplaces and technologies for the financial services and home services industries. It delivers measurable and cost-effective marketing results to its clients, in the form of qualified inquiries such as clicks, leads, calls, applications, or customers. It generates revenue by delivering measurable online marketing results to the clients. The company operates as one reportable segment. The company generates majority of revenue from United States. The company's products and services are Customer Acquisition, QuinStreet Rating Platform (QRP), and Cloud Control Media.

About ACRS Aclaris Therapeutics Inc.

Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.

Share on Social Networks: